The U.S. Acne drugs market size stood at USD 2.3 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Acne is a common dermatological condition, affecting more than 9.4 million worldwide. Abnormal hormone production is a key causative factor. Rise in androgen (oestrogen, in women) levels during puberty triggers the onset of this condition by enlarging oil glands under the skin. This leads to excessive sebum production, which breaks down cell walls in pores leading to bacterial invasion. Although some studies suggest that the risk of developing acne may be increased due to genetic causes, certain factors such as emotional stress, menstruation, hot and humid climate, and greasy cosmetics can trigger the condition.
Increasing prevalence and severity of acne will drive the U.S. market over the projection years. Acne vulgaris is the most common skin problem amongst the teenaged population, with women being affected at higher rates than men.
Various factors such as fluctuating hormone levels, unhygienic lifestyle, and excessive production of oil from sebaceous glands have increased the prevalence of acne, thereby positively affecting the market growth. In addition, western countries are more prone to acne due to the population’s dietary regimen characterized by high amounts of sugar, refined grains, high protein, and high-fat dairy products, hence boosting the market growth in countries such as U.S., UK, and France.